Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Payables (2016 - 2025)

Historic Payables for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $20.5 million.

  • CorMedix's Payables rose 142209.14% to $20.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 142209.14%. This contributed to the annual value of $1.7 million for FY2024, which is N/A changed from last year.
  • CorMedix's Payables amounted to $20.5 million in Q3 2025, which was up 142209.14% from $5.8 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Payables peaked at $20.5 million during Q3 2025, and registered a low of $943344.0 during Q2 2021.
  • Moreover, its 5-year median value for Payables was $2.1 million (2022), whereas its average is $3.2 million.
  • Per our database at Business Quant, CorMedix's Payables tumbled by 6069.4% in 2021 and then skyrocketed by 142209.14% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Payables stood at $2.2 million in 2021, then fell by 0.34% to $2.2 million in 2022, then increased by 8.35% to $2.4 million in 2023, then fell by 27.91% to $1.7 million in 2024, then surged by 1089.09% to $20.5 million in 2025.
  • Its last three reported values are $20.5 million in Q3 2025, $5.8 million for Q2 2025, and $1.9 million during Q1 2025.